Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
J Dent Res ; 100(9): 928-934, 2021 08.
Artículo en Inglés | MEDLINE | ID: mdl-33880960

RESUMEN

Previous reports suggest that periodontal treatment is associated with improved health care outcomes and reduced costs. Using data from the New York State Medicaid program, rates of emergency department (ED) use and inpatient admissions (IPs), as well as costs for ED, IPs, pharmacy, and total health care, were studied to determine the association of preventive dental care to health care outcomes. Utilization of dental services in the first 2 y (July 2012-June 2014) was compared to health care outcomes in the final year (July 2014-June 2015). Costs and utilization for members who did not receive dental services (No Dental) were compared to those who received any dental care (Any Dental), any preventive dental care (PDC), PDC without an extraction and/or endodontic treatment (PDC without Ext/Endo), PDC with an Ext/Endo (PDC with Ext/Endo), or Ext/Endo without PDC (Ext/Endo without PDC). Propensity scores were used to adjust for potential confounders. After adjustment, ED rate ratios were significantly lower for PDC and PDC without Ext/Endo but higher for the Any Dental and Ext/Endo without PDC. IP ratios were lower for all treatment groups except Ext/Endo without PDC. ED costs differed little compared to the No Dental group except for Ext/Endo without PDC. For IPs, costs per member were significantly lower for all groups (-$262.91 [95% confidence interval (CI), -325.40 to -200.42] to -$379.82 [95% CI, -451.27 to -308.37]) except for Ext/Endo without PDC. For total health care costs, Ext/Endo without PDC had a significantly greater total health care cost ($530.50 [95% CI, 156.99-904.01]). Each additional PDC visit was associated with a 3% reduction in the relative risk for ED and 9% reduction for IPs. Costs also decreased for total health care (-$235.64 [95% CI, -299.95 to -171.33]) and IP (-$181.39 [95% CI, -208.73 to -154.05]). In conclusion, an association between PDC and improved health care outcomes was observed, with the opposite association for Ext/Endo without PDC.


Asunto(s)
Costos de la Atención en Salud , Medicaid , Atención Odontológica , Humanos , New York , Evaluación de Resultado en la Atención de Salud , Estados Unidos
2.
Eur J Pharmacol ; 38(1): 183-7, 1976 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-954827

RESUMEN

I.v. administration of delta9-THC (2.5 mg/kg) To anesthetized dogs resulted in a decrease in heart rate, pulmonary blood flow (PBF), and a significant increase in pulmonary artery pressure (PAP) and total pulmonary vascular resistance (PVR). The increase in PVR to delta9-THC was significantly reduced by cardiac pacing, and was virtually abolished either by bilateral vagotomy or by pretreatment with hexamethonium. The data indicated the delta9-THC induced elevation of PVR was mediated via reflexogenic mechanisms involving afferent vagi and efferent autonomic pathways.


Asunto(s)
Cannabis/farmacología , Dronabinol/farmacología , Hemodinámica/efectos de los fármacos , Pulmón/irrigación sanguínea , Animales , Perros , Flujo Sanguíneo Regional/efectos de los fármacos
3.
Res Commun Chem Pathol Pharmacol ; 14(1): 201-4, 1976 May.
Artículo en Inglés | MEDLINE | ID: mdl-935652

RESUMEN

Chronic administration of delta9-tetrahydrocannabinol (delta9-THC) 1 mg/kg, s.c. twice a day for 7 days failed to produce any significant alterations in the peripheral autonomic transmission to the heart of mongrel dogs anesthetized with sodium pentobarbital. Prior to anesthesia, heart rate of the treated dogs was slightly greater than that of the placebo group. However, under pentobarbital anesthesia, heart rate of the delta9-THC treated animals was significantly lower than that of the placebo group. The data suggested that chronic delta9-THC may have an inhibitory effect on the central vagal structures and in addition, this agent antagonizes the ability of pentobarbital to elevate heart rate in dogs.


Asunto(s)
Cannabis/farmacología , Dronabinol/farmacología , Frecuencia Cardíaca/efectos de los fármacos , Anestesia , Animales , Perros , Interacciones Farmacológicas , Estimulación Eléctrica , Femenino , Corazón/fisiología , Masculino , Pentobarbital , Placebos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...